Incyte announces first patient treated in phase 3 clinical trial of itacitinib for GVD
Incyte announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for first-line treatment of patients with acute graft-versus-host disease. The trial will evaluate efficacy and safety of itacitinib, Incyte's novel, potent, and selective JAK1 inhibitor. July 20, 2017